化学
胶水
肺
病理
药理学
弥漫性肺泡损伤
病理生理学
肺损伤
外科
生物活性
作者
Luxiao Zhu,Dan Tang,Ting Chen,Chenhui Sun,Ke Dong,Q W Chen,戴勤学,莫云长,Pan Chen,Jinfeng Sun,Guang Liang,Qidong Tang
标识
DOI:10.1021/acs.jmedchem.6c00755
摘要
Myeloid differentiation factor 88 (MyD88) is a critical mediator of inflammatory signaling. However, the development of MyD88 inhibitors has been limited, and there are no reports on MyD88 degraders. Based on our previously identified MyD88 inhibitor c17 and employing a template-assisted modification strategy, we designed and synthesized 40 novel derivatives, and identified the optimal compound d21, which could inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway activation by facilitating the interaction between ring finger protein 126 (RNF126) (an E3 ubiquitin ligase) and MyD88, thereby promoting ubiquitination and subsequent degradation of MyD88. The subacute toxicity test indicated that d21 had good safety profile. Furthermore, it demonstrated significant anti-inflammatory effects in both cecal ligation and puncture (CLP) and lipopolysaccharide (LPS) induced acute lung injury (ALI) models, effectively ameliorating ALI symptoms. These findings suggest that d21 holds considerable promise as a MyD88-targeting molecular glue degrader for the treatment of ALI.
科研通智能强力驱动
Strongly Powered by AbleSci AI